Graybug Vision, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for diseases of the back of the eye. Founded in 2014 and headquartered in Redwood City, California, the company leverages its proprietary Depot™ sustained-release technology platform to create long-lasting intraocular treatments intended to reduce the treatment burden for patients living with chronic retinal diseases.
The company’s lead product candidate, GB-102, is a sustained-release formulation of sunitinib malate designed for the treatment of wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). GB-102 is delivered via a single intravitreal injection and is engineered to provide therapeutic levels of active drug over multiple months. In addition, Graybug is advancing GB-401, a sustained-release therapy targeting geographic atrophy secondary to dry AMD, with the goal of addressing unmet needs in retinal degenerative conditions.
Graybug Vision operates primarily in the United States but is actively engaging with regulatory authorities in Europe and other regions to support global development and potential commercialization. The company maintains a robust intellectual property portfolio covering its Depot™ platform and pipeline candidates, and collaborates with contract manufacturing organizations for clinical supply and scale-up activities. Key executive leadership includes Jeffrey S. Grossman as Chief Executive Officer and Dr. Paul Ashton as Chief Medical Officer, supported by a management team experienced in ophthalmology drug development and regulatory strategy.
Since its initial public offering on the Nasdaq Stock Market in 2019 under the ticker “GRAY,” Graybug Vision has focused its efforts on advancing clinical programs through Phase 1/2 and Phase 2 studies. The company continues to work closely with investigators, patient advocacy groups and global health authorities to accelerate development timelines and bring novel treatments to patients affected by vision-threatening eye diseases.
AI Generated. May Contain Errors.